Morgan Stanley Lowers Humana (NYSE:HUM) Price Target to $315.00

Humana (NYSE:HUM) had its price target decreased by equities research analysts at Morgan Stanley from $331.00 to $315.00 in a research report issued on Friday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the insurance provider’s stock. Morgan Stanley’s price objective would indicate a potential upside of 8.15% from the stock’s previous close.

A number of other equities research analysts also recently commented on the stock. UBS Group set a $36.00 price target on shares of Halliburton and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Credit Suisse Group reiterated a “buy” rating and set a $19.50 price target on shares of Infineon Technologies in a report on Thursday, May 2nd. Oppenheimer lowered their price target on shares of Littelfuse from $215.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. Barclays set a $24.00 price target on shares of Tenet Healthcare and gave the stock a “hold” rating in a report on Wednesday, April 17th. Finally, ValuEngine cut shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Humana presently has a consensus rating of “Buy” and an average price target of $336.42.

NYSE:HUM opened at $291.25 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The company’s 50-day simple moving average is $258.65. Humana has a twelve month low of $225.65 and a twelve month high of $355.88. The stock has a market cap of $39.33 billion, a P/E ratio of 20.02, a P/E/G ratio of 1.16 and a beta of 0.87.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.30 by $0.18. Humana had a net margin of 2.99% and a return on equity of 20.77%. The firm had revenue of $16.11 billion during the quarter, compared to the consensus estimate of $15.67 billion. During the same period last year, the firm posted $3.36 EPS. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. As a group, sell-side analysts predict that Humana will post 17.48 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. Destination Wealth Management lifted its position in shares of Humana by 130.0% during the first quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 65 shares in the last quarter. Evolution Wealth Advisors LLC acquired a new stake in Humana in the second quarter valued at $46,000. Sontag Advisory LLC acquired a new stake in Humana in the fourth quarter valued at $47,000. Zions Bancorporation N.A. acquired a new stake in Humana in the first quarter valued at $51,000. Finally, Berman Capital Advisors LLC raised its holdings in Humana by 152.3% in the first quarter. Berman Capital Advisors LLC now owns 217 shares of the insurance provider’s stock valued at $57,000 after acquiring an additional 131 shares in the last quarter. 92.61% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More: What can cause a stock to outperform?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.